Literature DB >> 27624901

Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women.

Siri Amundsen1,2, Torunn G Øvrebø3, Netta Marie S Amble3, Anne Christine Poole4, Hedvig Nordeng3.   

Abstract

PURPOSE: Migraine is highly prevalent among women of fertile age. The main objectives of this study were to describe the prevalence and patterns of use of antimigraine medications during pregnancy and breastfeeding and to identify maternal and migraine-related factors associated with medication use during pregnancy.
METHODS: The study is a cross-sectional internet-based survey among pregnant women and new mothers with migraine conducted in Norway from October 1, 2013 to February 1, 2014. Descriptive statistics were used to explore patterns of medication use, and logistic regression analysis was performed to examine the association between maternal socio-demographic and migraine-related factors and use of antimigraine medications during pregnancy.
RESULTS: Of the total 401 respondents, 34.9 % were pregnant and 65.1 % had delivered within the last 18 months. The majority reported use of antimigraine medications during pregnancy (73.3 %) and postpartum (64.8 %), yet less than a third considered their migraine to be optimally treated during pregnancy (31.7 %) and the breastfeeding period (27.2 %). The patterns of medication use markedly changed during pregnancy and postpartum. Women with moderate or severe migraine were more likely to use antimigraine medications during pregnancy compared to women with mild migraine.
CONCLUSIONS: Despite the fact that antimigraine medications were commonly used, the majority of the women felt that their migraine was suboptimally treated during pregnancy and postpartum. There was a decline in the use of medicines in pregnancy and postpartum, and the patterns of use markedly changed. Efforts to improve treatment of women with migraine during pregnancy and breastfeeding should be undertaken.

Entities:  

Keywords:  Breastfeeding; Drug therapy; Information needs; Migraine; Pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27624901     DOI: 10.1007/s00228-016-2127-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  36 in total

1.  Web-based questionnaires: the future in epidemiology?

Authors:  Marleen M H J van Gelder; Reini W Bretveld; Nel Roeleveld
Journal:  Am J Epidemiol       Date:  2010-09-29       Impact factor: 4.897

Review 2.  Epidemiology of headache in Europe.

Authors:  L J Stovner; J-A Zwart; K Hagen; G M Terwindt; J Pascual
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

3.  Delivery outcome after maternal use of drugs for migraine: a register study in Sweden.

Authors:  Bengt Källén; Emma Nilsson; Petra Otterblad Olausson
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

4.  Advice on drug safety in pregnancy: are there differences between commonly used sources of information?

Authors:  Sofia K Frost Widnes; Jan Schjøtt
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 5.  Contributions of epidemiology to our understanding of migraine.

Authors:  Kathleen R Merikangas
Journal:  Headache       Date:  2013-02       Impact factor: 5.887

6.  Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study.

Authors:  Dawn C Buse; Elizabeth W Loder; Jennifer A Gorman; Walter F Stewart; Michael L Reed; Kristina M Fanning; Daniel Serrano; Richard B Lipton
Journal:  Headache       Date:  2013-06-28       Impact factor: 5.887

7.  Canadian Headache Society guideline for migraine prophylaxis.

Authors:  Tamara Pringsheim; W Jeptha Davenport; Gordon Mackie; Irene Worthington; Michel Aubé; Suzanne N Christie; Jonathan Gladstone; Werner J Becker
Journal:  Can J Neurol Sci       Date:  2012-03       Impact factor: 2.104

8.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

9.  Medication in early pregnancy: prevalence of use and relationship to maternal characteristics.

Authors:  S Buitendijk; M B Bracken
Journal:  Am J Obstet Gynecol       Date:  1991-07       Impact factor: 8.661

10.  Multiple information sources and consequences of conflicting information about medicine use during pregnancy: a multinational Internet-based survey.

Authors:  Katri Hämeen-Anttila; Hedvig Nordeng; Esa Kokki; Johanna Jyrkkä; Angela Lupattelli; Kirsti Vainio; Hannes Enlund
Journal:  J Med Internet Res       Date:  2014-02-20       Impact factor: 5.428

View more
  7 in total

1.  Association of Maternal Use of Triptans During Pregnancy With Risk of Attention-Deficit/Hyperactivity Disorder in Offspring.

Authors:  Gerd Marie Harris; Mollie Wood; Eivind Ystrom; Hedvig Nordeng
Journal:  JAMA Netw Open       Date:  2022-06-01

2.  Patterns and predictors of analgesic use in pregnancy: a longitudinal drug utilization study with special focus on women with migraine.

Authors:  Gerd-Marie Eskerud Harris; Mollie Wood; Malin Eberhard-Gran; Christofer Lundqvist; Hedvig Nordeng
Journal:  BMC Pregnancy Childbirth       Date:  2017-07-14       Impact factor: 3.007

Review 3.  Migraine Treatment in Pregnancy and Lactation.

Authors:  Anne H Calhoun
Journal:  Curr Pain Headache Rep       Date:  2017-10-04

4.  Risk perception, beliefs about medicines and medical adherence among pregnant and breastfeeding women with migraine: findings from a cross-sectional study in Norway.

Authors:  Siri Amundsen; Torunn Gudmestad Øvrebø; Netta Marie Skretteberg Amble; Anne Christine Poole; Hedvig Nordeng
Journal:  BMJ Open       Date:  2019-02-27       Impact factor: 2.692

5.  Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.

Authors:  Fatima Tauqeer; Mollie Wood; Sarah Hjorth; Angela Lupattelli; Hedvig Nordeng
Journal:  PLoS One       Date:  2021-08-23       Impact factor: 3.240

6.  Medicines for headache before and during pregnancy: a retrospective cohort study (ATENA study).

Authors:  Chiara Lupi; Andrea Negro; Elisabetta Gambassi; Tommaso Susini; Pierangelo Geppetti; Silvia Benemei
Journal:  Neurol Sci       Date:  2020-09-23       Impact factor: 3.307

7.  Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.

Authors:  Anick Bérard; Shannon Strom; Jin-Ping Zhao; Shashi Kori; Detlef Albrecht
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.